captured official filings
AUTOMATED SEC FILING DILIGENCE BRIEF
PUBLIC-RECORD DELIVERY
OTC issuer
Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.
captured official filings
captured official filings
captured official filings
PRIORITY FILING CUES
What to review next
Rules are applied to retained SEC filing types in this issuer record. They prioritize reading work; they are not ratings or conclusions.
- WATCHF-1/A2026-07-16 · form-type review cueSEC source →
- WATCHF-1/A2026-07-15 · form-type review cueSEC source →
- WATCHF-1/A2026-06-16 · form-type review cueSEC source →
- WATCHF-1/A2026-06-08 · form-type review cueSEC source →
- WATCHF-1/A2026-05-18 · form-type review cueSEC source →
WHAT THIS AUTOMATES
One evidence index instead of a manual filing hunt.
It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.
PROFESSIONAL DELIVERY LAYER
What teams can pay to automate next.
Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.
MACHINE-DETECTED FILING CHANGE RADAR
Public registration text delta
Comparing F-1/A filed 2026-07-15 with F-1/A filed 2026-07-16.
Tracked-term count changes
Counts are navigation signals, not conclusions. Open both official filings to determine materiality.
- No tracked keyword-count change was detected in the cached plain-text excerpts.
Candidate disclosure excerpts
Only sentence-level additions or removals containing tracked diligence terms are shown. These are reading cues, not materiality findings.
New in latest filing
- Subject to completion, dated July 16 , 2026 PRELIMINARY PROSPECTUS 5,555,555 Ordinary Shares This is an initial public offering by Tarsier Pharma Ltd. of its ordinary shares, par value NIS 0.001 per share (the “ordinary shares”).
Present in earlier filing, not found in latest
- Subject to completion, dated July 14 , 2026 PRELIMINARY PROSPECTUS 5,555,555 Ordinary Shares This is an initial public offering by Tarsier Pharma Ltd. of its ordinary shares, par value NIS 0.001 per share (the “ordinary shares”).
Method: readable plain text is extracted from two official SEC HTML filings, then compared at sentence and tracked-term level. Formatting, exhibit differences and boilerplate may create false positives. This radar is not legal advice, a disclosure completeness opinion or a transaction recommendation.
What to verify next
Generated from retained official filing types and chronology. This is a work sequence, not legal, accounting, compliance, investment or transaction advice.
- Registration & offering path (6 retained)
Read the latest registration filing, then monitor for an amendment, EFFECT notice or 424B prospectus.
A dated Download Edition preserves this source-linked view for a project file.
Know what the paid record contains.
This is a dated working copy of the public issuer record, organized for a project file—not a separate data feed or an opinion.
6 retained SEC filingsLatest retained filing: 2026-07-16.Printable HTML record + CSV official-source indexOne issuer · one payment · no account
Best when you need to preserve what was visible, attach it to a project, or hand a source-linked record to a colleague, counsel or internal reviewer.
DOWNLOAD EDITION
Turn this issuer page into a project-file deliverable.
US$29 one time. For the moment you need to preserve the official record, hand it to a colleague or attach it to a deal file. No subscription, account or recurring charge. Download begins in this browser after payment is verified.
- Source-linked filing chronology and registration path
- Filing-change radar plus financing, legal, tax/lien and regulatory disclosure cues
- Official-source index for project-file archiving and downloadable CSV export
Best used whenYou need a dated, source-linked issuer record for a client, counsel, broker-dealer or internal review file.
Pay once · verified PayPal checkout · immediate HTML and CSV delivery.
AUTOMATED EVIDENCE SNAPSHOT
Unlock download · US$29Save this source-linked record
Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.
DISCLOSURE CONTEXT SCREEN
Specific public-record cues, separated from generic language
Reads selected SEC filing text by sentence. Contents-page labels, generic risk language and allocation discussion are excluded; historical financing language is kept separate.
- LEGAL
Indemnification of Directors and Officers Indemnification The Israeli Companies Law, 5759 -1999 (the “Companies Law”), and the Israeli Securities Law, 5728 -1968 (the “Securities Law”), provide that a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association includ
F-1/A · 2026-06-16 · official SEC source ↗ - FINANCING
” The sale of this SAFE also included, in the event of the occurrence of an equity financing, a warrant equal to one hundred percent (100%) of the holder’s SAFE purchase amount and exercisable at the conversion price of the May 2025 SAFE, and with a term of two years from such equity financing.
F-1/A · 2026-06-16 · official SEC source ↗ - FINANCING
” The May 2025 SAFE Warrant is issued upon and subject to the occurrence of an “equity financing” and its term is calculated beginning from the occurrence of such equity financing and for two years thereafter.
F-1/A · 2026-06-16 · official SEC source ↗ - FINANCING
Additionally, the sale of the November 2025 SAFEs included, in the event of occurrence of an equity financing, a warrant for each such SAFE equal to two hundred percent (200%) of the holder’s SAFE purchase amount and exercisable at the conversion price of the November 2025 SAFEs, and with a term of three years from the date of such equity financing.
F-1/A · 2026-06-16 · official SEC source ↗ - FINANCING
” Each of the November 2025 SAFEs Warrants is issued upon and subject to the occurrence of an “equity financing” (as defined in such SAFEs) and its term is calculated beginning from the occurrence of such equity financing and for three years thereafter.
F-1/A · 2026-06-16 · official SEC source ↗
Scope: automated text screening of selected SEC filings only. Each cue requires review of the linked filing; it does not confirm a claim, legal status, tax status, financing completion or current issuer condition.
LEGACY TERM SCREEN · SOURCE INDEX
Financing, legal and disclosure cues
This screen counts source documents with a reading cue, never the number of underlying events. A cue may be generic risk language; open the cited SEC source before drawing any conclusion.
View screened SEC sources (4)
Coverage boundary: this is a keyword screen of selected SEC filings only. It is not a court-docket search, tax-compliance review, lien clearance, sanctions screen, adverse-media search or a complete count of financings. A zero result means no matching term in the readable documents screened—not that the underlying issue is absent. Verify each cue in the linked official filing and use the appropriate independent professionals.
CAPITAL & OFFERING RECORD
Browse all captured financing filings →Official filing path for financing review
Registration, amendment, prospectus, shelf and current-report nodes are organized here as a reading path. Use the SEC source for terms, status and materiality.
- F-1/ARegistration amendmentOpen SEC source →
- F-1/ARegistration amendmentOpen SEC source →
- F-1/ARegistration amendmentOpen SEC source →
- F-1/ARegistration amendmentOpen SEC source →
- F-1/ARegistration amendmentOpen SEC source →
- F-1Initial registration statementOpen SEC source →
Interpretation boundary: filing counts are not financing-round counts, proceeds, closing status or current capitalization. A registration, prospectus or report can relate to different purposes; use the linked official filing and appropriate advisers to verify each event.
KEY OFFERING LANGUAGE
What the latest offering documents say
Candidate sentence excerpts from readable official SEC filing text. This provides a fast reading layer for offering structure and terms; it is not a normalized term sheet or a transaction conclusion.
Offering structure
Candidate language describing the securities or registration structure.
No sentence matching this reading cue was found in the 5 readable filings screened.Shares / price
Candidate language about shares, units or offering-price terms.
“” Certain of our officers, directors and greater than five percent (5%) shareholders have indicated interest in participating in this offering at the public offering price and on the same terms as the other purchasers in this offering.”F-1/A · 2026-07-16 · Open SEC source →
Use of proceeds
Candidate language describing stated proceeds or intended use.
“The date of this prospectus is               , 2026     Page About this Prospectus   iii Prospectus Summary   1 The Offering   10 Risk Factors   12 Cautionary Note Regarding Forward-Looking Statements   45 Use of Proceeds   47 Dividend Policy   49 Capitalization   50 Dilution”F-1/A · 2026-07-16 · Open SEC source →
Convertible / warrant terms
Candidate language about conversion, warrants or related instruments.
“” The sale of this SAFE also included, in the event of the occurrence of an equity financing, a warrant equal to one hundred percent (100%) of the holder’s SAFE purchase amount and exercisable at the conversion price of the May 2025 SAFE, and with a term of two years from such equity financing.”F-1/A · 2026-06-16 · Open SEC source →
View offering documents screened (5)
Extraction boundary: wording can be incomplete, duplicated, conditional or superseded by later filings. The system does not calculate proceeds, share counts, dilution or closing status from these excerpts. Verify every term in the linked official SEC filing.
OFFICIAL SEC SUBMISSIONS
Open Evidence Snapshot →Captured filing chronology
- F-1/ARegistration & offeringOpen SEC filing →
- F-1/ARegistration & offeringOpen SEC filing →
- F-1/ARegistration & offeringOpen SEC filing →
- F-1/ARegistration & offeringOpen SEC filing →
- F-1/ARegistration & offeringOpen SEC filing →
- F-1Registration & offeringOpen SEC filing →
Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.